DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of DNX-2401
that can be injected directly into brain tumors and into the surrounding brain tissue where
tumor cells can multiply. A second goal is to study how the new drug DNX-2401 affects brain
tumor cells and the body in general.